Avid Bioservices Inc.

NASDAQ: CDMOP · Real-Time Price · USD
25.06
0.01 (0.04%)
At close: Apr 24, 2025, 3:47 PM

Company Description

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture.

It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support.

The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization.

It serves biotechnology and pharmaceutical companies.

Avid Bioservices, Inc. has a process development and manufacturing agreement with Oragenics, Inc. to develop coronavirus vaccine.

The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018.

Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.

Avid Bioservices Inc.
Avid Bioservices Inc. logo
Country United States
IPO Date Jan 31, 2022
Industry Biotechnology
Sector Healthcare
Employees 222
CEO Richard B. Hancock

Contact Details

Address:
2642 Michelle Drive
Tustin, California
United States
Website http://avidbio.com

Stock Details

Ticker Symbol CDMOP
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0000704562
CUSIP Number 05368M205
ISIN Number US05368M2052
Employer ID 95-3698422
SIC Code 2834

Key Executives

No executives data available.

Latest SEC Filings

Date Type Title
May 15, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 18, 2025 15-12G Filing
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 07, 2025 4 Filing
Feb 07, 2025 4 Filing
Feb 07, 2025 4 Filing
Feb 07, 2025 4 Filing
Feb 07, 2025 4 Filing
Feb 07, 2025 4 Filing
Feb 07, 2025 4 Filing